The Bulletin
Men's Weekly


.

GenFleet Therapeutics to Present Phase I Data for GFH312 at 2023 American Society for Clinical Pharmacology & Therapeutics Meeting

  • Written by PR Newswire

SHANGHAI, March 9, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the results from phase I study of GFH312 (RIPK1 inhibitor) monotherapy will be presented as a poster at the 2023 ASCPT Meeting in Atlanta on March 22nd. GFH312 is safe...

The Bulletin Magazine

Your Reliable Partner for Every Roadside Emergency

Choosing Waterproofing Membranes for Outdoor Spaces: The Essential Attributes You Need

How Modular Content Accelerates Turnaround for Time-Sensitive Campaigns

How Litigation Lawyers in Sydney Can Help Resolve Disputes Efficiently

Revitalising Homes and Offices with Professional Carpet Cleaning Melbourne

Gum Grafting for Receding Gums: Cost, Recovery Time, and What to Expect

Why It’s Convenient to Buy Ceiling Fans Online

Creating Functional and Welcoming Spaces with a Professional Medical Clinic Fitout

10 Thoughtful Gift Ideas That Show You Truly Care

Debt Collection vs. Debt Recovery: What’s the Difference?

CHEAPER RIDES FOR FANS AS 13CABS CUTS FARES FOR FINALS WEEK

Therapeutic Approaches: CBT vs ACT for Depression